Literature DB >> 26551559

Update on pathology, staging and molecular pathology of endometrial (uterine corpus) adenocarcinoma.

Joanne K L Rutgers1.   

Abstract

Endometrial carcinoma is comprised of two major groups: type I that is hormonally driven with a good prognosis and type II that is hormone independent with a poor prognosis. The two most common subtypes are endometrioid adenocarcinoma, the prototypic type I cancer, and uterine serous carcinoma, the prototypic type II cancer, each with their own distinct precursor lesion. The histologic type, as codified by the WHO Tumor Classification system, grade, and stage are used to guide treatment. There is an increasing interest in screening for familial risk factors, specifically Lynch syndrome. A molecular classification of endometrial cancers holds promise for future improvements in care.

Entities:  

Keywords:  endometrial carcinoma; molecular subtypes; pathology; uterine cancer

Mesh:

Year:  2015        PMID: 26551559     DOI: 10.2217/fon.15.262

Source DB:  PubMed          Journal:  Future Oncol        ISSN: 1479-6694            Impact factor:   3.404


  12 in total

1.  Clinicopathologic Significance of Mismatch Repair Defects in Endometrial Cancer: An NRG Oncology/Gynecologic Oncology Group Study.

Authors:  D Scott McMeekin; David L Tritchler; David E Cohn; David G Mutch; Heather A Lankes; Melissa A Geller; Matthew A Powell; Floor J Backes; Lisa M Landrum; Richard Zaino; Russell D Broaddus; Nilsa Ramirez; Feng Gao; Shamshad Ali; Kathleen M Darcy; Michael L Pearl; Paul A DiSilvestro; Shashikant B Lele; Paul J Goodfellow
Journal:  J Clin Oncol       Date:  2016-06-20       Impact factor: 44.544

2.  Epigenetic changes as prognostic predictors in endometrial carcinomas.

Authors:  Sanja A Farkas; Bengt G Sorbe; Torbjörn K Nilsson
Journal:  Epigenetics       Date:  2016-11-22       Impact factor: 4.528

3.  Post-transcriptional Regulation of MMP16 and TIMP2 Expression via miR-382, miR-410 and miR-200b in Endometrial Cancer.

Authors:  Beata Rak; Dawid Mehlich; Filip Garbicz; Zofia Domosud; Wiktor Paskal; Janina M Marczewska; Paweł K Włodarski
Journal:  Cancer Genomics Proteomics       Date:  2017 Sep-Oct       Impact factor: 4.069

4.  Prognostic importance of DNA ploidy in non-endometrioid, high-risk endometrial carcinomas.

Authors:  Bengt Sorbe
Journal:  Oncol Lett       Date:  2016-02-02       Impact factor: 2.967

5.  Are the uterine serous carcinomas underdiagnosed? Histomorphologic and immunohistochemical correlates and clinical follow up in high-grade endometrial carcinomas initially diagnosed as high-grade endometrioid carcinoma.

Authors:  Shaomin Hu; Jeff L Hinson; Rahul Matnani; Michael L Cibull; Rouzan G Karabakhtsian
Journal:  Mod Pathol       Date:  2017-10-06       Impact factor: 7.842

6.  The panoramic picture of pepsinogen gene family with pan-cancer.

Authors:  Shixuan Shen; Hao Li; Jingwei Liu; Liping Sun; Yuan Yuan
Journal:  Cancer Med       Date:  2020-10-17       Impact factor: 4.452

7.  Bioinformatics analysis of RNA sequencing data reveals multiple key genes in uterine corpus endometrial carcinoma.

Authors:  Liang Shen; Ming Liu; Wei Liu; Jing Cui; Changzhong Li
Journal:  Oncol Lett       Date:  2017-11-03       Impact factor: 2.967

8.  Identification of a six-gene signature with prognostic value for patients with endometrial carcinoma.

Authors:  Yizi Wang; Fang Ren; Peng Chen; Shuang Liu; Zixuan Song; Xiaoxin Ma
Journal:  Cancer Med       Date:  2018-10-10       Impact factor: 4.452

9.  Clinical and Expression Significance of AKT1 by Co-expression Network Analysis in Endometrial Cancer.

Authors:  Xiao Huo; Hengzi Sun; Qian Liu; Xiangwen Ma; Peng Peng; Mei Yu; Ying Zhang; Dongyan Cao; Keng Shen
Journal:  Front Oncol       Date:  2019-11-06       Impact factor: 6.244

10.  Pan-cancer analysis of alternative splicing regulator heterogeneous nuclear ribonucleoproteins (hnRNPs) family and their prognostic potential.

Authors:  Hao Li; Jingwei Liu; Shixuan Shen; Di Dai; Shitong Cheng; Xiaolong Dong; Liping Sun; Xiaolin Guo
Journal:  J Cell Mol Med       Date:  2020-09-11       Impact factor: 5.310

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.